key: cord-0685368-dm7rysvj
authors: Pandey, Satish Chandra; Pande, Veni; Sati, Diksha; Upreti, Shobha; Samant, Mukesh
title: Vaccination strategies to combat novel corona virus SARS-CoV-2
date: 2020-06-12
journal: Life Sci
DOI: 10.1016/j.lfs.2020.117956
sha: d44e447cb7a9d3ee11901f3be108166a1d480de8
doc_id: 685368
cord_uid: dm7rysvj

The 2019-novel coronavirus disease (COVID-19) is caused by SARS-CoV-2 is transmitted from human to human has recently reported in China. Now COVID-19 has been spread all over the world and declared epidemics by WHO. It has caused a Public Health Emergency of International Concern. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Due to the rapid increase of SARS-CoV-2 infections and unavailability of antiviral therapeutic agents, developing an effective SAR-CoV-2 vaccine is urgently required. SARS-CoV-2 which is genetically similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) is an enveloped, single and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins which are very similar to SARS-CoV and MERS-CoV proteins. In this review we have summarized various vaccine candidates i.e., nucleotide, subunit and vector based as well as attenuated and inactivated forms, which have already been demonstrated their prophylactic efficacy against MERS-CoV and SARS-CoV, so these candidates could be used as a potential tool for the development of a safe and effective vaccine against SARS-CoV-2.

J o u r n a l P r e -p r o o f various other DNA vaccines including AIDS [34] , malaria and influenza [35] are also under human trial.

DNA vaccine made up of plasmid DNA encoding protein from pathogens have been demonstrated for inducing both T and B cell responses, after showing the similar effects of live viruses, that antigenic proteins are produced endogenously and presented efficiently by MHC class I, thus help in inducing CD8+ T-cell responses [36] . Further as the DNA vaccines are simple, stable, safe and can be easily produced it can be possible option to the use of live vaccines [36] . There are numbers of SARS-CoV proteins viz. S [24, 28, [37] [38] [39] [40] , M [41] and N [42, 43] proteins reported to induce cellular and humoral responses have been utilized as DNA vaccine candidates [40] . In a study DNA vaccine associated expression of S protein have generated both T-cell and neutralizing antibody responses, and lowered the replication of SARS-CoV in the respiratory tract this manifested that protective efficacy to the S gene in mice was antibody mediated not T-cell dependent [24] . Further in a study S plasmid improved the gene expression of spike (S) protein by heterologous viral RNA export elements and protection in mouse model [39] , but their role have not been recorded in case of other in vivo models. Vaccination of mice with multi-epitope DNA vaccine has elicited specific antibody response to two candidate epitopes, S(437-459) and M(1- 20) which reduced the virulence of SARS-CoV in-vitro, but there was no report on the protective efficacy [41] . In another study mice Immunized with N-DNA vaccine induced Nspecific antibody response and Tc-cell activity [42, 44] , moreover a strong delayed-type hypersensitivity (DTH) and CD8(+) CTL responses to N protein was observed [44] . In an another study of N-DNA vaccination, expression of N protein and its linkage to LAMP for better presentation of MHC II has amplified memory response [45] . Moreover vaccination J o u r n a l P r e -p r o o f of C57BL/6 mice with naked CRT/N DNA for improved MHC class I presentation not only induced N-specific humoral and cellular immunity but also considerably reduced the titer of challenging vaccinia virus against the cells expressing N protein [43] . In addition to other animal models, an N-DNA vaccine candidate has also been evaluated in HLA-transgenic mice that induced a specific CD8+ T-cell response [46] . Besides the expression of S and N proteins, M protein have also been reported to be expressed in mice and found to induce neutralizing antibodies, human monoclonal antibodies and cytotoxic T-lymphocyte response [47] . In a comprehensive study of DNA vaccine using different gene fragments (S-, M-and N), M DNA vaccine was reported with the highest cellular immunity in mice [40] . Although DNA vaccines works efficiently during preclinical stages, but their efficacy in field conditions are quite unsatisfactory and have lower immunogenicity [48] , as compared to other vaccines such as inactivated and live-attenuated virus vaccines and need further improvement regarding the efficacy. To confront this problem different prime-boost approaches such as heterologous prime or boost with proteins, inactivated viral vaccine candidates or viral vectors have been constructed [28, 41, [49] [50] [51] .

There are various practices mostly the traditional one that has been approached to make a vaccine, but these methods on an average takes, 16 years as in the case from human papilloma virus, to rotavirus. The development of a protein-based vaccine requires growth of the viruses and its protein purification, which is a lengthy process and may take several years.

To make an effective and new generation vaccine against this fast spreading virus, instead of protein, mRNA vaccination strategy can be a better approach [52] . The mRNA J o u r n a l P r e -p r o o f vaccine manifests the immune responses similar to natural infection and provides a short synthetic viral mRNA, which is then used by the host to produce the antigen proteins. Since the mRNA used in vaccine after injected can't integrate into the host's genome, they are safe to use. Furthermore, they are safer than inactivated or protein based vaccines because they are free from the risk of protein contamination or the injected virus to become active.

The huge benefit of mRNA vaccine is that it can circumvent the hassle associated with the purification of viral proteins that saves the time from months to years used in standardization and scaling up the mass production [52] . So far there is no approved RNA 

Considering safety efficacy, subunit vaccines involving pure antigens are said to be advantageous, as the constituent only includes synthetic peptides or recombinant proteins that expresses only particular fragments of immunogen, excluding the participation of contagious viruses. In addition to this, subunit vaccines are less prone to generate the side effects at the site of inoculation. Due to stable conditions and definite fragments of pathogen, subunit vaccines achieve reliable production. Due to all these qualities of subunit vaccines are helpful in making it an interesting candidate for vaccine. A number of structural proteins comprising spike (S), envelope (E), membrane (M), and nucleocapsid (N) are expressed by SARS-CoV that may act as antigens to activate neutralizing antibodies and generate defensive response.

Spike protein (S) of virus performs significant part in entering the host [57] . The CoV-RNA genome is allowed to go inside the cells of host through the early interactions of S1 domain to its receptor in the host i.e. PP 4 in MERS-CoV and ACE2 in SARS-CoV, followed by the viral and host membrane fusion facilitated by the S2 segment. To develop vaccines based on CoV subunit, S proteins are the preferred candidate, because S proteins have sites for binding of receptor as well as for membrane fusion; vaccines based on S protein are likely to J o u r n a l P r e -p r o o f activate antibodies that prevent the binding of virus and later fusion of membranes as well thereby counteracting infection of virus [58] . S glycoprotein of SARS-CoV which is shown to bind the cellular receptor angiotensin-converting enzyme 2 (ACE2), is an interesting candidate to target for both vaccine and therapeutic improvement [32, 59] . This practice is robustly encouraged by the discovery that illustrates the infectivity by SARS-CoV is powerfully counteracted by human mAb that binds to S protein through N-terminal and thereby prevents binding of receptor by hindering the formation of syncytia [60] . On the other hand, few epitopes that are not neutralizing are also present in the immmunopredominant sites of the S protein of SARS-CoV [61] that could elicit the immune responses which might be harmful [62] . For that reason, the identification and elimination of such epitopes in S protein is obligatory. Moreover, the S protein have been reported to produce serum neutralizing antibodies and protected African green monkeys and mice challenged with SARS-CoV [24, 63] . S-ectodomain proteins of full length merged with/ without S or Sfoldon i.e. fold on trimeric motif, may induce precise antibody response and neutralizing antibody thus causing protection of the vaccinated mice to SARS-CoV infection [64] .

Besides this, S protein associated with SARS-CoV is also shown to be responsible for eliciting responses by T-cell (CD4+ and CD8+ ) [49] .

RBD is a segment in the centre of S1 subunit of S protein which is ~193 AA residues and binds to receptors present in the target cells. It has been illustrated that antisera of SARS infected person and that of animals inoculated with inactivated SARS-CoV, effectively responded with RBD [65, 66] . A lot of the neutralizing antibodies were removed of these antisera by RBD through antibodies absorption, while the antibodies specific to RBD, having effective neutralizing action were obtained from these antisera [66] . It has also been J o u r n a l P r e -p r o o f represented that the RBD vaccinated mice and rabbits produces counteracting antibodies in high number against the SARS-CoV having 50% neutralizing titers at a >1:10,000 serum dilution [67] . As compared to S protein of full length, high number of neutralizing antibodies were induced with RBD [24, 67, 68] because in contrast to S protein with full length, no immunodominant regions are present in RBD that elicits antibodies that are not neutralizing. To prevent the infection from SARS-CoV, with different genotypes RBD containing recombinant proteins or vectors that encodes RBD could be used. Thus, the generation of antibodies targeting the RBD subunit of SARS-CoV-2 would be an important preventive and treatment strategy that can be tested further in suitable models before clinical trials.

Besides the above mentioned proteins, expression of various other proteins have also been reported on the virion surface with the production of antibodies in SARS patients serum [69] , further these proteins can also be evaluated to check the protective efficacy against SARS-CoV. For instance, counteracting action of the antibodies towards M proteins has also been reported [70] . Membrane or M protein plays an essential role in upholding the configuration of viral envelope [71] and M protein carries out this by making interactions with different CoV proteins [72] , incorporating Golgi complex into novel virions [71] , and stabilizing proteins of the nucleocapsid [71] . Investigations on animal CoV vaccines have reported that the Nucleocapsid protein (N) of CoV could serve as additional target for the development of vaccine [73] . Even though the antibodies to N proteins of CoV does not have mechanism to neutralize the virus, but generation of CoV-restricted CD8+ T cells has J o u r n a l P r e -p r o o f been reported [74] [75] [76] , consequently providing protection subsequent to infection in animals [77] therefore, this suggest that in vivo defense could be offered by the protein by eliciting cell-mediated response [74, 78] . Research have shown that precise IgG antibodies, as well as subtypes IgG1 and IgG2a were induced when Freund's adjuvant was conjugated with SARS-CoV N protein that was plant expressed while, conjugating adjutants like cysteinephosphate-guanine (CpG) and Montanide ISA-51 with N protein that was E. coli-expressed, results in induction of definite IgG antibodies toward a Th1 (IgG2a)-type response in mice [79, 80] . However, the conserved N protein across CoV families implies that it is not a suitable candidate for vaccine development, and the antibodies against the N protein of SARS-CoV-2 do not provide immunity to the infection [81] .

Recombinant vector vaccines can be defined as live, dividing viruses that are genetically manipulated to harbor some additional pathogenic gene, coding for foreign proteins, responsible for eliciting immune response [82] . Recombinant vector vaccines are highly efficient in triggering an immune response as they can infect cells and sustain in the body for quite a long time and can react to antigen-presenting cells directly. Also viral proteins in such vaccines can act like adjuvant [83] , thereby enhancing immune response, resulting in generating more antibodies and long-term immunity, and reducing the dose of antigen 

Adenovirus based delivery systems have several benefits including their ease of administration by oral or nasal route, their non-pathogenicity in humans [84] , particularly for mutants with compromised replication [85] . Defending power of Ad-vectored vaccines against SARS-CoV was first demonstrated in rhesus macaques in 2003 [86] . They were immunized with three Ad5-SARS-CoV Ad-based vector constructs expressing genes for N, S and M proteins. The vaccine induced antibody reaction against spike S1 fragment, production of SARS-CoV neutralizing antibodies and T-cell proliferation against the N protein [86] . In a similar study when Ad vector expressing SARS N-protein was used to vaccinate C57BL/6 strain mice, surprisingly no neutralizing antibodies were produced but SARS-CoV-specific IFN-γ secretion and T-cell production was detected [84] . When 129S6/SvEv strain mice was co-immunized with 2 Ad vector constructs containing genes coding for SARS-CoV S and N proteins by either nasal or muscular route, it suggested that former induced Ig A and effectively checks SARS-CoV reproduction in nasal and alveolar tissues while the later works by proliferating neutralizing antibodies [87] . A number of studies analyzing efficacy of these vaccines have been done in ferrets, being it the only model that resembles most of the symptoms of human patients including fever, transmission by respiratory route, discharge of virus from upper airways and lung injuries [88] , [89] .

When ferrets were primed with adenoviral construct coding S-protein and boosted with a different adenovirus from chimpanzee, a significant reduction in viral load and other clinical J o u r n a l P r e -p r o o f symptoms was observed [90] . Targeting that serotype to which humans are naïve is the focal point of recent adenoviral constructs. For this Chimpanzee adenovirus (ChAdOx1) is a promising candidate owing to its lack of persistent immunity in humans [91] and superior safety status. Presently, a potential MERS-CoV vaccine named MERS001 is at clinical trial, having ChAdOx1coding for S-protein of MERS-CoV [92] . But restricted cloning ability, limited host range [93] and pre-existent immunity against adenovirus in significant proportion of human population [83, 94] are some of their limitations which makes their animal testing challenging and retards their clinical use as a vector for vaccine designing.

The Poxvirus constructs are potent vectors due to better stability, greater insert size, easy production, cytoplasmic gene expression and capacity to elicit long-termed cell mediated and humoral immunity [83] . In a study, replication-compromised poxvirus vector, modified vaccinia Ankara (MVA) strain, coding for SARS-CoV S protein, generate neutralizing antibody response and reduced viral load in the upper airways of mice [63] . MVA constructs expressing entire S protein are potent vaccine target [95] [96] [97] . An additional vaccine target is MVA-MERS-S, presently in phase I clinical trial at University Medical Center Hamburg-Eppendorf, Germany [98] . Studies involving relatively conserved N protein expressing MVA in mice generated CD8 + cells [99] .

Newcastle disease virus (NDV) viral-vector contain MERS-CoV S protein which generated neutralizing antibody response in BALB/c mice and Bactrian camels [100] . Although NDV J o u r n a l P r e -p r o o f vaccines elicited vigorous immune response, but also have many limitations namely, persistent immunity against NDV, higher threat of pathogenesis, low viral titer production, and possible carcinogenesis [101] .

Since viral vector-based vaccines could be quickly constructed and used without an adjuvant, development of such vaccines might be possible in SARS-CoV-2 because RBD of S-protein has been identified as a neutralizing epitope [102] . So this epitope could be actively pursued for the development of viral vector based vaccines. [109] . Thus, deletion of the structural E gene may prove to be the first step in the field of developing a live-attenuated vaccine against SARS-CoV. Moreover, nsp-1 gene deleted CoV mouse hepatitis virus (MHV) has also been reported with high efficacy thus can also be used for developing a SARS-attenuated vaccine [110] . Two studies related to gene deletion and attenuation effects suggests that removal of ORFs 3a, 3b, 6, 7a, 7b, 8a, 8b or 9b results in very little and no viral replication during in-vitro and in vivo conditions [108, 111] . However the outcomes of the studies conducted so far are not so convincing because it takes longer time to create non infectious clones of coronavirus due to larger genome size and also requires extensive safety testing [112] . Furthermore, reversion of the pathogen to the virulent form can be protected using gene replacement knockout strategy that can be safer as compared to the lines developed by other means like chemical treatment and irradiation etc.

Inactivated virus vaccines also known as the WKV (whole Killed Virus) vaccines represent a pathogen whose ability to infect and replicate has been ceased, consequently making it sterile but retaining its ability to act as an immunogen, so that the immune system could still work if such a pathogen is injected into a host. Inactivated vaccines are prepared by neutralizing the pathogen as a whole by chemicals or by heat and radiation. It is thought that inactivated vaccines can be prepared with much less effort which makes them one of the attractive types of vaccines prepared in the market today. These vaccines work by exposing the same epitopes which a virus otherwise would have presented, thus eliciting an immune response. When sera of the infected person were tested, presence of antibodies against minimum eight different proteins suggests the presence of diverse moieties exposed on the membrane of the pathogen [69] . In order to search targets for the protective antibodies further investigations has been done and it is found that additional structural proteins that can be targeted are encoded by (Open Reading Frame) ORFs (3a, 6, 7a and 7b), envelope (E), spike (S), and matrix (M) [49, [113] [114] [115] [116] . By interpreting these data we can assume that multiple targets are present for the protective antibodies. 3CL, nucleocapsid (N), S, M etc. are the proteins against which the antibodies were induced when a mice was vaccinated with SARS-CoV [117] . Despite many advantages there are some limitations for the development of inactivated vaccines viz. budding pathogens in bulk (biosafety level 3) and complete sterilization of the grown pathogens. Successful sterilization of SARS-CoV, in bulk has been demonstrated with the help of UV radiations [118] . During the last two decades many investigators have demonstrated that inactivated whole SARS-CoV can induce SARS-CoV neutralizing antibody [65, 117, [119] [120] [121] [122] but there have no study been reported against the live SARS-CoV challenge. A study in BALB/c mice, WKV vaccine was observed to Journal Pre-proof J o u r n a l P r e -p r o o f provide resistance by ceasing the multiplication of pulmonary SARS-CoV, however immunological responses are yet to be verified [123] . Further, β-propiolactone inactivated WKV SARS-CoV (Tor-2 strain) reported to be a potential vaccine candidate as it induced neutralizing antibodies and was able to minimize the virus load in the pulmonary tract of the mouse model [87] . However, there are less evidences of the mouse models being infected by such a diseases clinically, thus studying models where this strain is more virulent and sustainable is imperative. So WKV has also been tested in ferrets, a model which show significant lung pathology and clinical sign [89, 90] . Formalin inactivated Urbani strain of SARS-CoV did not demonstrated strong immune response [124] but β-propiolactone inactivated WKV SARS-CoV induced significant neutralizing antibody and reduced virus replication in respiratory tract of ferrets [89] . Rhesus monkeys were also been tested for the formaldehyde inactivated SARS-CoV vaccines and shown to be safe and immunogenic [125] . WKV SARS-CoV has also been tested in humans and found to be safe and elicited SARS-CoV specific neutralizing antibodies, however the efficiency the vaccine in humans yet to be reported [126] . These data suggested that WKV vaccines are safe and they are able to induce SARS-CoV specific neutralizing antibodies so inactivated viral vaccines could also be evaluated as potential vaccine candidate against SARS-CoV-2. might be considered as a good vaccine antigen because it induces neutralizing antibodies that prevent host cell attachment and infection [127] [128] [129] . Further nucleic acid based vaccine, showed the most advance platform in response to emerging pathogens. DNA vaccine was the first vaccine candidate that entered in clinical trial (NCT02809443) [130] less than 1-year after the zika virus outbreak. Another nucleic acid-based vaccine, m-RNA vaccine can be considered as advanced vaccine technology because of its stability and protein translation efficiency so that it could induce robust immune responses [52, 131] .

Currently there are various biopharmaceutical companies or academic sectors are in the race to develop the prophylactic SAR-CoV-2 vaccine by using several platforms including mRNA, DNA, vaccinia or adenoviral vector and recombinant protein [112, 132] . In order to make effective SAR-CoV-2 vaccine possible, target antigen(s)/nucleotide identification, immunization route, immune protection, suitable animal models, scalability, production facility, target product profile (TPP), outbreak forecasting and target population etc. are important parameters. As it is already known for some of the recent epidemics (Zika and Ebola) whose successful vaccine has not been developed yet. Lesson-learned from these epidemics in order to speed up the available vaccine during ongoing outbreak, preclinical studies of SAR-CoV-2 vaccine candidates may need to be performed in parallel with clinical trials. But in reality, SARS-CoV-2 vaccines will not be available for another 12- 

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan

A novel coronavirus from patients with pneumonia in China

Another decade, another coronavirus

When will a coronavirus vaccine be ready? The Guardian

History and recent advances in coronavirus discovery

Coronaviruses: an overview of their replication and pathogenesis

Cryo-electron tomography of mouse hepatitis virus: insights into the structure of the coronavirion

Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy

Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv

Coronavirus infections-more han just the common cold

Animal coronaviruses: What can they teach us about the severe acute respiratory syndrome?

Q&A: The novel coronavirus outbreak causing COVID-19

Mechanisms of coronavirus cell entry mediated by the viral spike protein

From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design

Membrane binding proteins of coronaviruses

SARS vaccines: where are we? Expert review of vaccines

Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E

An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine

Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors

Novel viral vectors in infectious diseases

Molecular mechanisms for enhanced DNA vaccine immunogenicity

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

RNA sensors of the innate immune system and their detection of pathogens

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response

Exosomes in the nose induce immune cell trafficking and harbour an altered protein cargo in chronic airway inflammation

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

Emergence of Zaire Ebola virus disease in Guinea

Coronavirus infections of man associated with diseases other than the common cold

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

Rapid response research -SARS coronavirus vaccines and application of processes to other emerging infectious diseases

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

Human immunodeficiency virus vaccine trials

Clinical applications of DNA vaccines: current progress

DNA vaccines: immunology, application, and optimization

Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments

Optimization of a DNA vaccine against SARS

Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS

Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice

A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro

Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus

Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine

SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both J o u r n a l P r e -p r o o f exogenous recombinant and endogenous DNA-encoded immunogens

Induction of Tcell response by a DNA vaccine encoding a novel HLA-A* 0201 severe acute respiratory syndrome coronavirus epitope

Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models

Animal models and vaccines for SARS-CoV infection

Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses

Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines

Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene

mRNA vaccines-a new era in vaccinology

Structure, function, and evolution of coronavirus spike proteins

The spike protein of SARS-CoV-a target for vaccine and therapeutic development

Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus

Severe acute respiratory syndrome (SARS) -paradigm of an emerging viral infection

Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome J o u r n a l P r e -p r o o f (SARS) coronavirus: implication for developing SARS diagnostics and vaccines

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates

Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system

SARS corona virus peptides recognized by antibodies in the sera of convalescent cases

Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine

Coronavirus envelope protein: current knowledge

Coronavirus structural proteins and virus assembly

A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination

Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal infection without eliminating virus from the central nervous system

Characterization of mouse hepatitis virus-specific cytotoxic T cells derived from the central nervous system of mice infected with the JHM strain

Localization of a T-cell epitope within the nucleocapsid protein of avian coronavirus

Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry

Development of protection against coronavirus induced diseases

Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Return of the Coronavirus: 2019-nCoV

Recombinant vector vaccine evolution

Recombinant viruses as tools to induce protective cellular immunity against infectious diseases

Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice

Recombinant viruses as vaccines and immunological tools

Effects of a SARS-associated coronavirus vaccine in monkeys

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus

The SARS-CoV ferret model in an infection-challenge study

Severe acute respiratory in ferrets: whole killed virus and adenovirus-vectored vaccines

Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Adenovirus vectors as recombinant viral vaccines

Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies

Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein

& Becker, S. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

Health NIo. Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S

CD8+ T cells responding to the middle east respiratory syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice

& Bu, Z. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization

Developments in viral vector-based vaccines

Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses

Efficacy and safety of rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates

Rubella virus: mechanism of attenuation in the vaccine strain (HPV77)

Vaccinia virus: a suitable vehicle for recombinant vaccines?

Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria

A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo

Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice

A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters

Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines

Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice

SARS-CoV-2 Vaccines: Status Report

Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation

Severe acute respiratory syndrome coronavirus 3a protein is a viral structural protein

The ORF7b protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is expressed in virus-infected cells and incorporated into SARS-CoV particles

The severe acute respiratory syndrome coronavirus 3a is a novel structural protein

Immunogenicity of SARS inactivated vaccine in BALB/c mice

Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen

A subcutaneously injected UVinactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice

Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain

SARS vaccine protective in mice

Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys

Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine

Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein

The spike protein of SARS-CoV--a target for vaccine and therapeutic development

Receptorbinding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model

Safety and immunogenicity of an anti-Zika virus DNA vaccine-preliminary report

mRNA as a transformative technology for vaccine development to control infectious diseases

The SARS-CoV-2 Vaccine Pipeline: an Overview